Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review
Paul Hammerness, Katherine McCarthy, Elizabeth Mancuso, Cassandra Gendron, Daniel Geller
Clinical and Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital and Harvard Medical School, Cambridge, MA, USA
Objective: This review examines and summarizes the pharmacodynamic and pharmacokinetic properties, short- and longer-term efficacy, the moderating effect of comorbid disorders, as well as short- and long-term safety and tolerability of atomoxetine for the treatment of pediatric attention-deficit/hyperactivity disorder (ADHD).
Methods: A systematic literature search was performed to review the extant literature on articles pertaining to the pharmacological treatment with atomoxetine in pediatric and/or adolescent ADHD.
Results: There is an extensive literature on atomoxetine; over 4000 children have participated in clinical trials of atomoxetine, demonstrating its short- and longer-term efficacy. In addition, studies have examined the moderating effect of comorbid disorders on atomoxetine response, as well as atomoxetine’s therapeutic potential for other psychiatric conditions. Short- and longer-term safety and tolerability continue to be reported.
Conclusions: Atomoxetine is indicated for both acute and maintenance/extended treatment of pediatric ADHD. Clinicians and families must be familiar with atomoxetine’s evidence base, including its profile of clinical response and its possible effectiveness in the presence of comorbidity.
Keywords: ADHD, atomoxetine, pediatric
This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php
Readers of this article also read:
Sex differences in the prediction of the effectiveness of paroxetine for patients with major depressive disorder identified using a receiver operating characteristic curve analysis for early response [Corrigendum]
Tomita T, Norio YF, Sato Y, Nakagami T, Tsuchimine S, Kaneda A, Kaneko S
Published Date: 5 June 2014
Published Date: 16 April 2014
Cetinkaya A, Erden A, Avci D, Karagoz H, Karahan S, Basak M, Bulut K, Gencer V, Mutlu H
Published Date: 27 February 2014
Tat peptide-decorated gelatin-siloxane nanoparticles for delivery of CGRP transgene in treatment of cerebral vasospasm [Corrigendum]
Tian XH, Wang ZG, Meng H, Wang YH, Feng W, Wei F, Huang ZC, Lin XN, Ren L
Published Date: 13 June 2013
Radiofrequency-targeted vertebral augmentation versus traditional balloon kyphoplasty: radiographic and morphologic outcomes of an ex vivo biomechanical pilot study [Erratum]
Published Date: 5 June 2013
Qu X, Yao C, Wang J, Li Z, Zhang Z
Published Date: 26 April 2013
Mizoguchi T, Ozaki M, Unoki K, Dake Y, Eto T, Arai M
Published Date: 26 October 2012
Wu Q, Chu M
Published Date: 15 August 2012
Concentration- and time-dependent response of human gingival fibroblasts to fibroblast growth factor 2 immobilized on titanium dental implants
Ma Q, Wang W, Chu PK, Mei S, Ji K, Jin L, Zhang Y,
Published Date: 17 April 2012
Espandar L, Sikder S, Moshirfar M
Published Date: 6 February 2011